About cAMP-dependent protein kinase type I-beta regulatory subunit
cAMP-dependent protein kinase type I-beta regulatory subunit (PRKAR1B) is a protein
from Homo sapiens identified by UniProt accession
P31321, 381 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | cAMP-dependent protein kinase type I-beta regulatory subunit |
| UniProt accession | P31321 |
| Gene | PRKAR1B |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (66)
Diseases linked to this target (Open Targets).
- Marbach-Schaaf neurodevelopmental syndrome · score 0.60
- primary ciliary dyskinesia · score 0.54
- hemoglobin measurement · score 0.42
- hematocrit · score 0.41
- erythrocyte count · score 0.38
- amino acid measurement · score 0.37
- red blood cell density measurement · score 0.36
- neurodegenerative disease · score 0.33
- Varicose veins · score 0.31
- histidine measurement · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31321-F1 | alphafold | PREDICTED | 86.93 | — |
Amino-acid sequence (381 residues)
MASPPACPSE EDESLKGCEL YVQLHGIQQV LKDCIVHLCI SKPERPMKFL REHFEKLEKE ENRQILARQK SNSQSDSHDE EVSPTPPNPV VKARRRRGGV SAEVYTEEDA VSYVRKVIPK DYKTMTALAK AISKNVLFAH LDDNERSDIF DAMFPVTHIA GETVIQQGNE GDNFYVVDQG EVDVYVNGEW VTNISEGGSF GELALIYGTP RAATVKAKTD LKLWGIDRDS YRRILMGSTL RKRKMYEEFL SKVSILESLE KWERLTVADA LEPVQFEDGE KIVVQGEPGD DFYIITEGTA SVLQRRSPNE EYVEVGRLGP SDYFGEIALL LNRPRAATVV ARGPLKCVKL DRPRFERVLG PCSEILKRNI QRYNSFISLT V
Explore cAMP-dependent protein kinase type I-beta regulatory subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets